Hypogammaglobulinemia after front-line immunochemotherapy in patients with follicular lymphoma.

Autor: Díaz Acedo, Rocío, Artacho Criado, Silvia, Ríos Herranz, Eduardo, Gutiérrez Pizarraya, Antonio, Sánchez Romero, Irene, Márquez Saavedra, Esther
Předmět:
Zdroj: Journal of Oncology Pharmacy Practice; Dec2023, Vol. 29 Issue 8, p1982-1989, 8p
Abstrakt: Introduction: Hypogammaglobulinemia after front-line immunochemotherapy for follicular lymphoma is a poorly studied adverse event that could be related to the appearance of severe and/or recurrent non-neutropenic infections which could affect the quality of life of the patients, even motivating a need of long-term replacement therapy with human immunoglobulins. Methods: Observational, retrospective study aiming to estimate the incidence of hypogammaglobulinemia, as well as its severity and clinical consequences, and to explore possible predictive factors for its development. Specific immunoglobulin deficiencies were also studied. Results: 76.5% of patients had hypogammaglobulinemia during or after front-line treatment, mostly grade 1-2; with 38.8% patients who developed clinically relevant infections and 20% patients requiring human immunoglobulins replacement therapy. A high-risk FLIPI score was identified as a risk factor for hypogammaglobulinemia (ods ratio: 4.51; 95% confidence interval: 1.29–15.68; p < 0.001) and basal gamma globulin level as a protective factor (odds ratio: 0.92; 95% confidence interval: 0.988–0.996; p = 0.018). Any type of immunochemotherapy regimen was associated with different risks of hypogammaglobulinemia in our study. Conclusions: Hypogammaglobulinemia appears in a high percentage of patients with follicular lymphoma in a real-world population, identifying a high-risk FLIPI score as a risk factor for its development and basal gamma globulins as a protective factor. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: